Jamel Sawyer is one of a growing number of Americans to suffer from a deadly infection called MRSA (methicillin-resistant Staphylococcus aureus). One of the most notorious multidrug-resistant superbugs, MRSA is responsible for an estimated 19,000 deaths and 360,000 hospitalizations each year in this country. Fortunately, Jamel survived the infection, but the disease left him paralyzed below the waist.
Jamel’s story illustrates the twin dangers presented by emerging multidrug-resistant bacterial infections and the waning effectiveness and availability of drugs to treat them.
Download the full PDF for more information.
Nearly a year after the enactment of the Generating Antibiotic Incentives Now Act, the U.S. Food and Drug Administration has released draft guidance for industry on developing antibacterial therapies for patients with unmet medical needs.
More infoAs multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options.
More info"As a nation, we need to exercise greater care with our use of antibiotics, in both humans and animals, so that these medications remain effective in treating serious bacterial infections."
More infoCopyright(c) 1996-2012 The Pew Charitable Trusts. All Rights Reserved.
[+] Feedback PHG.PRODUCTION.1.20130703.1022 (PEWSUWVMWAPP01)
